BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

656 related articles for article (PubMed ID: 17921898)

  • 21. Impact of FDG-PET/CT imaging on nodal staging for head-and-neck squamous cell carcinoma.
    Murakami R; Uozumi H; Hirai T; Nishimura R; Shiraishi S; Ota K; Murakami D; Tomiguchi S; Oya N; Katsuragawa S; Yamashita Y
    Int J Radiat Oncol Biol Phys; 2007 Jun; 68(2):377-82. PubMed ID: 17321066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preoperative Positron Emission Tomography for Node-Positive Head and Neck Cutaneous Squamous Cell Carcinoma.
    Hirshoren N; Olayos E; Herschtal A; Ravi Kumar AS; Gyorki DE
    Otolaryngol Head Neck Surg; 2018 Jan; 158(1):122-126. PubMed ID: 28925330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapy Response Assessment and Patient Outcomes in Head and Neck Squamous Cell Carcinoma: FDG PET Hopkins Criteria Versus Residual Neck Node Size and Morphologic Features.
    Wray R; Sheikhbahaei S; Marcus C; Zan E; Ferraro R; Rahmim A; Subramaniam RM
    AJR Am J Roentgenol; 2016 Sep; 207(3):641-7. PubMed ID: 27341273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Limitations of PET/CT in determining need for neck dissection after primary chemoradiation for advanced head and neck squamous cell carcinoma.
    Lyford-Pike S; Ha PK; Jacene HA; Saunders JR; Tufano RP
    ORL J Otorhinolaryngol Relat Spec; 2009; 71(5):251-6. PubMed ID: 19776658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Results of pretherapeutic lymph node diagnosis in head and neck tumors. Clinical value of 18-FDG positron emission tomography (PET)].
    Di Martino E; Nowak B; Krombach GA; Sellhaus B; Hausmann R; Cremerius U; Büll U; Westhofen M
    Laryngorhinootologie; 2000 Apr; 79(4):201-6. PubMed ID: 10838683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer.
    Mehanna H; McConkey CC; Rahman JK; Wong WL; Smith AF; Nutting C; Hartley AG; Hall P; Hulme C; Patel DK; Zeidler SV; Robinson M; Sanghera B; Fresco L; Dunn JA
    Health Technol Assess; 2017 Apr; 21(17):1-122. PubMed ID: 28409743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma.
    Roh JL; Yeo NK; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2007 Oct; 43(9):887-93. PubMed ID: 17207656
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma.
    Schwartz DL; Ford E; Rajendran J; Yueh B; Coltrera MD; Virgin J; Anzai Y; Haynor D; Lewellyn B; Mattes D; Meyer J; Phillips M; Leblanc M; Kinahan P; Krohn K; Eary J; Laramore GE
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):129-36. PubMed ID: 15629603
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
    Schaefferkoetter JD; Carlson ER; Heidel RE
    J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic value of only 18F-fluorodeocyglucose positron emission tomography/computed tomography-positive lymph nodes in head and neck squamous cell carcinoma.
    Lee SH; Huh SH; Jin SM; Rho YS; Yoon DY; Park CH
    Otolaryngol Head Neck Surg; 2012 Oct; 147(4):692-8. PubMed ID: 22535915
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of cervical lymph node metastases using FDG-PET in patients with head and neck cancer.
    Yamazaki Y; Saitoh M; Notani K; Tei K; Totsuka Y; Takinami S; Kanegae K; Inubushi M; Tamaki N; Kitagawa Y
    Ann Nucl Med; 2008 Apr; 22(3):177-84. PubMed ID: 18498032
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Response evaluation after chemoradiotherapy for advanced nodal disease in head and neck cancer using diffusion-weighted MRI and 18F-FDG-PET-CT.
    Schouten CS; de Graaf P; Alberts FM; Hoekstra OS; Comans EF; Bloemena E; Witte BI; Sanchez E; Leemans CR; Castelijns JA; de Bree R
    Oral Oncol; 2015 May; 51(5):541-7. PubMed ID: 25725587
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neck dissection planning based on postchemoradiation computed tomography in patients with head and neck cancer.
    Langerman A; Comstock R; Konda S; Abramovitch A; Kasza K; Vokes EE; Stenson KM
    Arch Otolaryngol Head Neck Surg; 2009 Sep; 135(9):876-80. PubMed ID: 19770419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer.
    McCollum AD; Burrell SC; Haddad RI; Norris CM; Tishler RB; Case MA; Posner MR; Van den Abbeele AD
    Head Neck; 2004 Oct; 26(10):890-6. PubMed ID: 15390197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of outcomes with delayed (18)F-FDG PET-CT response assessment in head and neck squamous cell carcinoma.
    Slevin F; Subesinghe M; Ramasamy S; Sen M; Scarsbrook AF; Prestwich RJ
    Br J Radiol; 2015 Aug; 88(1052):20140592. PubMed ID: 26081447
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes after primary chemoradiotherapy for N3 (>6 cm) head and neck squamous cell carcinoma after an FDG-PET--guided neck management policy.
    Adams G; Porceddu SV; Pryor DI; Panizza B; Foote M; Rowan A; Burmeister B
    Head Neck; 2014 Aug; 36(8):1200-6. PubMed ID: 23893554
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Utility of positron-emission tomography/computed tomography imaging in the management of the neck in recurrent laryngeal cancer.
    Gilbert MR; Branstetter BF; Kim S
    Laryngoscope; 2012 Apr; 122(4):821-5. PubMed ID: 22344673
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Value of fluoro-2-deoxy-D-glucose-positron emission tomography for detecting metastatic lesions in head and neck cancer.
    Fogh SE; Kubicek GJ; Champ C; Intenzo C; Axelrod R; Keane WM; Machtay MM
    Am J Clin Oncol; 2012 Aug; 35(4):311-5. PubMed ID: 22772424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Positron emission tomography in surveillance of head and neck squamous cell carcinoma after definitive chemoradiotherapy.
    Wang YF; Liu RS; Chu PY; Chang FC; Tai SK; Tsai TL; Huang JL; Chang SY
    Head Neck; 2009 Apr; 31(4):442-51. PubMed ID: 19177422
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Screening for distant metastases before salvage surgery in patients with recurrent head and neck squamous cell carcinoma: a retrospective case series comparing thoraco-abdominal CT, positron emission tomography and abdominal ultrasound.
    Fakhry N; Michel J; Colavolpe C; Varoquaux A; Dessi P; Giovanni A
    Clin Otolaryngol; 2012 Jun; 37(3):197-206. PubMed ID: 22520870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.